Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amebiasis: an update.

S L Reed1

  • 1Division of Infectious Diseases, UCSD Medical Center, California 92103-8416.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|February 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human coronavirus-NL63 infection is not associated with acute Kawasaki disease.

Advances in experimental medicine and biology·2006
Same author

Microbes and microbial toxins: paradigms for microbial-mucosal interactions. VI. Entamoeba histolytica: parasite-host interactions.

American journal of physiology. Gastrointestinal and liver physiology·2001
Same author

Degradation of bovine complement C3 by trichomonad extracellular proteinase.

Veterinary immunology and immunopathology·2001
Same author

Cysteine proteinases and the pathogenesis of amebiasis.

Clinical microbiology reviews·2001
Same author

Homology modeling of Entamoeba histolytica cysteine proteinases reveals the basis for cathepsin L-like structure with cathepsin B-like specificity.

Archives of medical research·2000
Same author

Role of the Entamoeba histolytica Gal/GalNAc lectin in recruiting proteins to the host:parasite interface.

Archives of medical research·2000
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Larger Blood Volume Increases Detection of Fastidious Mycobacteria and Fungi in Blood Culture.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Anticalcitonin: Limited utility of a context-dependent biomarker demonstrated in another real-world data set.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Procalcitonin Testing in Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Amebiasis, caused by Entamoeba histolytica, affects global health, presenting asymptomatically in most but causing severe illness in others. This review covers diagnosis, treatment, and future management strategies for amebiasis.

Area of Science:

  • Infectious Diseases
  • Public Health
  • Parasitology

Background:

  • Amebiasis is a global health concern, not limited to developing nations.
  • Most infections with Entamoeba histolytica are asymptomatic, but severe manifestations like dysentery and abscesses can occur.
  • Challenges in developed countries include managing asymptomatic infections and diagnosing amebiasis in immunocompromised patients (e.g., those with AIDS).

Purpose of the Study:

  • To review the diverse clinical presentations of amebiasis.
  • To discuss current indications for Entamoeba histolytica treatment.
  • To highlight recent advancements in amebiasis diagnosis and therapy.

Main Methods:

  • Review of clinical manifestations of amebiasis.
  • Analysis of diagnostic improvements.

Related Experiment Videos

  • Evaluation of therapeutic strategies.
  • Discussion of emerging research in amebiasis management.

    • Main Results:

    • Entamoeba histolytica causes a spectrum of disease, from asymptomatic carriage to invasive conditions.
    • Effective diagnostic tools and treatments are crucial for managing amebiasis.
    • Asymptomatic infections and amebiasis in specific patient groups (e.g., AIDS) pose diagnostic and therapeutic dilemmas.

    Conclusions:

    • Amebiasis requires global attention due to its varied clinical impact.
    • Improved diagnostic and therapeutic approaches are enhancing amebiasis patient care.
    • Ongoing research promises further advancements in the future management of amebiasis.